| Zone des professionnels de la santé > La vitamine E ralentit la progression de la maladie d’Alzheimer |
| 1. | Martin A, Youdim K, Szprengiel A, Shukitt-Hale B, Joseph J. Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr Rev 2002; 60(10 Pt 1): 308-26. | | 2. | Esposito E, Rotilio D, Di Matteo V, Di Giulio C, Cacchio M, Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 2002; 23(5): 719-35. | | 3. | Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002; 33(2): 182-91. | | 4. | Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Arch Neurol 2002; 59(7): 1125-32. | | 5. | Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287(24): 3230-7. | | 6. | Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287(24): 3223-9. | | 7. | Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002; 61(2): 191-202. | | 8. | Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001; 66(2): 163-70. | | 9. | Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18(9): 685-716. | | 10. | Miller JW. Vitamin E and memory: is it vascular protection? Nutr Rev 2000; 58(4): 109-11. | | 11. | Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54(6): 1265-72. | | 12. | Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 2000; 28(3): 351-60. | | 13. | Nourhashemi F, Gillette-Guyonnet S, Andrieu S, Ghisolfi A, Ousset PJ, Grandjean H et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000; 71(2): 643S-9S. | | 14. | Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71(2): 630S-6S. | | 15. | Tabet N, Birks J, Grimley Evans J. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000(4): CD002854. | | 16. | Pereira C, Santos MS, Oliveira C. Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 1999; 6(3): 209-19. | | 17. | Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 1998; 13(12): 840-5. | | 18. | Subramaniam R, Koppal T, Green M, Yatin S, Jordan B, Drake J et al. The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid beta-peptide(25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. Neurochem Res 1998; 23(11): 1403-10. | | 19. | Koppal T, Subramaniam R, Drake J, Prasad MR, Dhillon H, Butterfield DA. Vitamin E protects against Alzheimer's amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res 1998; 786(1-2): 270-3. | | 20. | Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336(17): 1216-22. | | 21. | Zhou Y, Gopalakrishnan V, Richardson JS. Actions of neurotoxic beta-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. J Neurochem 1996; 67(4): 1419-25. | | 22. | Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal, NT, Scherr PA. Relation of the tocopherol forms to incident Alzheimer disease and the cognitive change. American Journal of Clinical Nutrition 2005; 81: 508-14. | | 23. | Peterson RC, Thomas RG, Grundman M, Bennett D, Doody R. Vitamin E and Donepezil for the treatment of mild cognitive impairment. The New England Journal of Medicine 2005; 352 (23): 2379-88. | | 24. | Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer’s Disease, Parkinson Disease, Tardive Dyskinesia and Cataract: Part 2. The Annals of Pharmacotherapy 2005; 39 (12): 2065-72. | | 25. | Boothby LA, Doering PL. Vitamin C and Vitamin E for Alzheimer disease. The Annals of Pharmacotherapy 2005; 39 (12): 2073-80. | | 26. | Tabet N, Birks j, Grimley Evans J, Orrel M, Spector A. The Cochrane database of systematic reviews: Vitamin E for Alzheimer’s disease. Febuary 22, 2005. |
|
|
